(secondQuint)Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137).

 This is a phase 1b/3, multicenter, clinical trial.

 The study will be conducted in 2 parts (phase 1b and phase 3).

 In phase 1b talimogene laherparepvec will be administered in combination with pembrolizumab to approximately 40 subjects with recurrent or metastatic SCCHN.

 DLT will be evaluated based on the first 18 DLT-evaluable subjects.

 An expansion cohort of up to an additional 22 treated subjects will be enrolled to further evaluate the safety and to estimate the efficacy of the combination of talimogene laherparepvec with pembrolizumab to support a decision to initiate the phase 3 study.

.

 Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)@highlight

A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck